SIRPA and non-small cell lung carcinoma: We then examined the baseline abundance of SPP1 + SIRPα + macrophages in NSCLC patients [21] treated with immunotherapy and found that responders showed a higher baseline signature score of SPP1 + SIRPα + macrophages (Fig. 5F).